Chargement en cours...
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...
Enregistré dans:
| Publié dans: | Leuk Lymphoma |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/ https://ncbi.nlm.nih.gov/pubmed/32133897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|